No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
BLFS240517C17500
- 2.60
- +1.10+73.33%
15min DelayClose May 10 15:55 ET
2.60High2.60Low
2.60Open1.50Pre Close5 Volume5 Open Interest17.50Strike Price1.30KTurnover158.71%IV2.87%PremiumMay 17, 2024Expiry Date2.04Intrinsic Value100Multiplier4DDays to Expiry0.56Time Value100Contract SizeAmericanOptions Type0.7596Delta0.0882Gamma7.52Leverage Ratio-0.1221Theta0.0016Rho5.71Eff Leverage0.0069Vega
Intraday
- 5D
- 1D
News
BioLife Solns Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 30.21% Benchmark → $25 Upgrades Neutral → Buy 04/04/2024 14.58% Jefferies → $22 Initiates Cover
Benchmark Upgrades BioLife Solutions to Buy From Hold With $25 Price Target
BioLife Solutions (BLFS) has an average buy rating and a price target range of $20 to $30, according to analysts polled by Capital IQ.
Express News | BioLife Solutions Inc : Benchmark Raises to Buy
Several BioLife Solutions Insiders Sell Shares Sending Potential Negative Signal
BioLife Solutions, Inc. (NASDAQ:BLFS) shareholders may have reason to be concerned, as several insiders sold their shares over the past year. When evaluating insider transactions, knowing whether in
BioLife Solutions | 10-Q: Quarterly report
BioLife Solutions, Inc. (NASDAQ:BLFS) Q1 2024 Earnings Call Transcript
Comments
BioLife Solutions, despite more cash than debt, is seen as risky due to lack of profitability and negative cash flow. The company's future financial health hinges on its earnings.
Is BioLife Solutions (NASDAQ:BLFS) Using Too Much Debt? 1
The stock's low price indicates a potential buying opportunity. However, its high beta suggests volatility. The company's optimistic future outlook isn't fully reflected in the current share price.
BioLife Solutions' worrying forecast of increased losses and reduced revenues could wane investor confidence. The company's long-term business trajectory is vital for creating shareholder value.
Lack of insider transactions might be discouraging for the company's share outlook and the stated insider ownership is not really impressive.
Core points:
1. There are three platforms: first, cell processing, which includes biopreservation media and Sexton cell processing products; second is our freezers and thaw systems platform comprised of cryogenic liquid nitrogen freezers and Sterling ULT mechanical freezers and automated thawing Instruments; and finally, storage and storage services, which includes our SciSafe storage services and our evo col...
1. There are three platforms: first, cell processing, which includes biopreservation media and Sexton cell processing products; second is our freezers and thaw systems platform comprised of cryogenic liquid nitrogen freezers and Sterling ULT mechanical freezers and automated thawing Instruments; and finally, storage and storage services, which includes our SciSafe storage services and our evo col...
Read more